Recurrence rates and long-term survival in women diagnosed with breast cancer at age 40 and younger.

70 Background: Young age at diagnosis of breast cancer has been reported to be an independent risk factor for disease recurrence. However, there is little data on long term survival of young patients. We present long term follow up of a large cohort of women diagnosed with breast cancer at age 40 and younger. We determined rates of loco-regional recurrence (LRR), distant recurrence, and overall survival and adjusted for the patient and tumor characteristics which potentially predict outcomes. Methods: Following Institutional Review Board approval, data from the medical records of 628 women diagnosed with breast cancer at age 40 or younger between 1996 and 2008 were collected. Survival curves were estimated using the Kaplan Meier method. Results: Median age was 37 years (range: 21-40) and median follow-up was 72 months (range: 5-177). The rates of LRR as a first site of recurrence were 5.56% at 5 years and 12.11% at 10 years. In the entire population, with median follow-up of 72 months, there was no difference in the rates of loco-regional failure between patients who underwent breast conserving therapy (7.34%) compared to mastectomy (7.40%) (p=0.980). The rates of distant recurrence as a first event were 10.65% at 5 years and 14.58% at 10 years. Overall survival was 93.1% at 5 years and 87.26% at 10 years. 79.1% of patients received systemic therapy. For patients who developed disease recurrence, either LRR or distant, median time to first recurrence was 35 months (range: 3-167). Conclusions: Women aged 40 and younger at diagnosis of breast cancer have a good prognosis, with low overall recurrence rates at 5 and 10 years. Local recurrence in our cohort is lower than in prior studies, suggesting advances in therapy have made breast conservation a safe option in young breast cancer patients.

Download Full-text

Post-surgical depressive symptoms and long-term survival in non-metastatic breast cancer patients at 11-year follow-up

General Hospital Psychiatry ◽

10.1016/j.genhosppsych.2016.10.002 ◽

2017 ◽

Vol 44 ◽

pp. 16-21 ◽

Cited By ~ 16

Author(s):

Michael H. Antoni ◽

Jamie M. Jacobs ◽

Laura C. Bouchard ◽

Suzanne C. Lechner ◽

Devika R. Jutagir ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Depressive Symptoms ◽

Cancer Patients ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Term Survival ◽

Long Term Survival

Download Full-text

Effective Local Control and Long-Term Survival in Patients with T4 Locally Advanced Breast Cancer Treated with Breast Conservation Therapy

Annals of Surgical Oncology ◽

10.1245/aso.2004.02.003 ◽

2004 ◽

Vol 11 (9) ◽

pp. 854-860 ◽

Cited By ~ 50

Author(s):

Jeannie Shen ◽

Vicente Valero ◽

Thomas A. Buchholz ◽

S. Eva Singletary ◽

Frederick C. Ames ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Local Control ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Breast Conservation ◽

Breast Conservation Therapy ◽

Term Survival ◽

Long Term Survival

Download Full-text

Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy

The Women s Oncology Review ◽

10.1080/14733400500035008 ◽

2005 ◽

Vol 5 (1) ◽

pp. 71-72

Author(s):

Baiba Grube

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Local Control ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Breast Conservation ◽

Breast Conservation Therapy ◽

Term Survival ◽

Long Term Survival

Download Full-text

Predictive factors for achieving a pathologic complete remission (pCR) rate after neoadjuvant radiochemotherapy in locally advanced noninflammatory breast cancer: Results of a multivariant analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.e11556 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. e11556-e11556

Author(s):

Edwin Boelke ◽

Christiane Matuschek ◽

Stephan L. Roth ◽

Hans Bojar ◽

Johann Wolfgang Janni ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Complete Remission ◽

Predictive Factors ◽

Locally Advanced ◽

Time Interval ◽

Term Survival ◽

Long Term Survival ◽

Pathologic Complete Remission

e11556 Background: In contrast to neoadjuvant chemotherapy they are no predictive factors to estimate the pathologic complete remission (pCR) rate after preoperative chemotherapy (NRT-CHX) in locally advanced breast cancer (LABC). Methods: 315 LABC patients were included in this trial. They were treated during 1991-1998. The last follow up was in November 2011. Radiotherapy was applied with 50 Gy (5x2 Gy / week) to the breast and the supra-/infraclavicular lymph nodes. 101 patients received a 10 Gy interstitial boost (breast conservation). Chemotherapy (CMF, EC or Mitoxantron was applied in 192 patients prior to radiotherapy and in 113 patients simultaneously. Ten patients had no chemotherapy. Age, tumor grade, nodal status, hormone receptor status, simultaneous vs. sequential CHX and the time period up to surgery were examined in multivariate terms for pCR and overall survival. Results: The pCR rate for NRT-CHX after surgery was 29.2%. In multivariante analysis a longer time interval to surgery increased the probability of a pCR (HR 1,17 [95% CI 1,05-1,31], p<0,01). In term of overall survival, the achievement of a pCR is the strongest predictor for long term survival (HR 0,28 [95% CI 0,19-0,56], p<0,001). Conclusions: A long time interval to surgery (> 2 months) increases the probability of a pCR after NRT-CHX. Like in neoadjuvant CHX the achievement of a pCR is an important prognostic factor for long term survival.

Download Full-text

Factors Associated with Recurrence Rates and Long-Term Survival in Women Diagnosed with Breast Cancer Ages 40 and Younger

Annals of Surgical Oncology ◽

10.1245/s10434-016-5404-z ◽

2016 ◽

Vol 23 (10) ◽

pp. 3212-3220 ◽

Cited By ~ 12

Author(s):

Jennifer K. Plichta ◽

Upahvan Rai ◽

Rong Tang ◽

Suzanne B. Coopey ◽

Julliette M. Buckley ◽

...

Keyword(s):

Breast Cancer ◽

Recurrence Rates ◽

Term Survival ◽

Long Term Survival ◽

Factors Associated

Download Full-text

Long-term Outcomes of Pregnancy-Associated Breast Cancer: A Single Institution Experience

Liaquat National Journal of Cancer Care ◽

10.37184/lnjcc.2789-0112.2.2 ◽

2021 ◽

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Long Term Outcomes ◽

Single Institution ◽

Term Survival ◽

Long Term Survival ◽

Response To Chemotherapy ◽

Her 2

Background: The incidence of pregnancy-associated breast cancer (PABC) is increasing, especially in the developed countries. Herein, we report the long-term outcomes of PABC from a single institution in an Arab country. Methods: Consecutive patients diagnosed to have PABC between 2005 and 2012 at a tertiary referral hospital from a Gulf cooperation council country were the subjects of the study. Long-term outcomes are reported, with a minimum follow-up of 8 years. Results: A total of 16 patients were evaluable for long-term survival analysis. The median age at the time of diagnosis was 31.5 (26-40) years. Nine (56%) patients were multiparous (> 5 previous pregnancies). The mean gestational age at diagnosis was 19.7±7.4 weeks. Immunohistochemistry revealed the following phenotypes: Luminal A 3 (18.8%); HER-2 enriched 8 (50%); triple-negative 5 (31.2%). Three patients underwent modified radical mastectomy as the initial treatment, of which 2 received adjuvant chemotherapy during pregnancy. For patients who received neoadjuvant or palliative chemotherapy, the response rate was 75% (pCR 2; CR 1; PR 6). After a median follow-up of 60 months, median progression-free survival was 36 months (95%CI 24.2 to 47.8), while the overall survival was 59 months (95%CI 31.6 – 86.4). Age, marker status, Ki-67 score, clinical stage and differentiation grade did not affect the PFS or OS on univariate analysis. Conclusions: Fifty percent of the patient with PABC expressed HER-2/neu protein, and 1/3rd had triple-negative disease. The rate of response to chemotherapy, and long-term survival may help to set a benchmark for studies from the region. Larger cohort studies may help to draw firm conclusions.

Download Full-text

Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial

Frontiers in Oncology ◽

10.3389/fonc.2021.720044 ◽

2021 ◽

Vol 11 ◽

Author(s):

Lili Mao ◽

Ya Ding ◽

Xue Bai ◽

Xinan Sheng ◽

Jie Dai ◽

...

Keyword(s):

Overall Survival ◽

Cutaneous Melanoma ◽

Objective Response ◽

Chinese Patients ◽

Term Survival ◽

Long Term Survival ◽

Acral Melanoma ◽

Long Term Follow Up

ObjectivesTo examine the long-term survival outcome of dabrafenib in combination with trametinib in Chinese patients with unresectable or metastatic acral/cutaneous melanoma with BRAF-V600 mutation and to explore potential predictors of effectiveness.MethodsThis was a long-term follow-up of Chinese patients with unresectable or metastatic BRAF V600-mutant acral/cutaneous melanoma administered dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily) in an open-label, multicenter, single-arm, phase IIa study (NCT02083354). Efficacy endpoints included objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). The impacts of baseline characteristics on PFS and OS were analyzed.ResultsA total of sixty patients were included. The median age was 48 years, and 24 patients (40.0%) were male. Totally 12 individuals (20.0%) had acral melanoma, and 45 (75.0%) had failed previous systemic therapy. Up to July 2020, the median duration of follow-up was 37.0 (95% confidence interval [CI] 29.1-44.9) months. The updated ORR was 71.7% (95%CI 60.3%-83.1%). The 3-year OS rate was 28.8% (95%CI 19.1-43.6%) in the overall population, and 35.7% (95%CI 15.5–82.4%) in acral melanoma patients. The median DOR was 7.5 months (95%CI 4.5 to 10.5). Baseline normal lactic dehydrogenase (LDH), metastatic organ sites<3 and complete response to combination therapy with dabrafenib plus trametinib were associated with improved PFS and OS.ConclusionDabrafenib combined with trametinib confer long-term survival in Chinese patients with BRAF V600-mutant, unresectable or metastatic acral/cutaneous melanoma.Clinical Trial Registrationhttps://clinicaltrials.gov/ct2/show/NCT02083354, identifier NCT02083354.

Download Full-text

Epirubicin Increases Long-Term Survival in Adjuvant Chemotherapy of Patients With Poor-Prognosis, Node-Positive, Early Breast Cancer: 10-Year Follow-Up Results of the French Adjuvant Study Group 05 Randomized Trial

Journal of Clinical Oncology ◽

10.1200/jco.2005.05.059 ◽

2005 ◽

Vol 23 (12) ◽

pp. 2686-2693 ◽

Cited By ~ 123

Author(s):

Jacques Bonneterre ◽

Henri Roché ◽

Pierre Kerbrat ◽

Alain Brémond ◽

Pierre Fumoleau ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Poor Prognosis ◽

Cardiac Toxicity ◽

Study Group ◽

Term Survival ◽

Long Term Survival ◽

Patients With Poor Prognosis

Purpose The French Adjuvant Study Group 05 (FASG-05) showed that fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 100 mg/m2 (FEC 100) was superior to the same regimen with epirubicin 50 mg/m2 (FEC 50) in terms of disease-free survival (DFS) and overall survival (OS) in adjuvant treatment of early breast cancer. We report 10-year data on efficacy, and long-term side effects for FASG-05. Patients and Methods We randomly assigned 565 patients to treatment with FEC 50 or FEC 100 after surgery. Postmenopausal patients also received tamoxifen for 3 years, and almost all patients (96%) also received radiotherapy. Results Median follow-up was 110 months. The 10-year DFS was 45.3% (95% CI, 41.9% to 48.7%) with FEC 50 and 50.7% (95% CI, 47.3% to 54.1%) with FEC 100 (Wilcoxon P = .036; log-rank P = .08). The 10-year OS was 50.0% (95% CI, 46.7% to 53.3%) with FEC 50 and 54.8% (95% CI, 51.3% to 58.3%) with FEC 100 (Wilcoxon P = .038; log-rank P = .05). Delayed cardiac toxicity (before relapse) occurred in four patients (1.5%) in the FEC 50 arm and three patients (1.1%) in the FEC 100 arm. Cardiac toxicity after relapse occurred in six (4.3%) and five (4.1%) patients treated with FEC 50 and FEC 100, respectively. Conclusion Treatment with adjuvant FEC 100 demonstrated superior DFS and OS versus FEC 50 at 10 years of follow-up. This survival advantage was not offset by long-term complications such as cardiac toxicity and second malignancy. Given the risk-benefit ratio, FEC 100 is a more optimal regimen for long-term survival in patients with poor prognosis.

Download Full-text